Calcifediol (25-OH Vitamin D).

Calcifediol is converted to the active hormone that induces TRPV6 and calbindin in the gut wall, the transporters that carry calcium across it. Without calcium in the meal there is nothing for that machinery to move.

The hydroxylases that make and clear vitamin D metabolites, including CYP27B1 and CYP24A1, are magnesium-dependent, and so is the binding protein that carries them in blood. Low magnesium slows the step that converts calcifediol into the active hormone.

Vitamin D signalling raises production of osteocalcin and matrix Gla protein, and vitamin K carboxylates their glutamate residues so they can bind calcium. D makes the protein, K activates it.

The vitamin D receptor works as a heterodimer with the retinoid X receptor, so retinoid status shapes its transcription. A large preformed retinol load can compete for that shared partner and blunt the D signal.

The vitamin D receptor binds DNA through two zinc-finger motifs, so its DNA-binding domain needs zinc to hold shape.

Calcifediol is already 25-hydroxylated, so it raises 25-OH-D faster than cholecalciferol, which must pass through the liver first. Stacking both feeds one pool from two entry points and total vitamin D activity should be counted once, not twice.

Calcifediol is fat-soluble and is taken up in mixed micelles, so a meal or capsule containing long-chain fat raises the fraction absorbed compared with taking it on an empty stomach.

Boron intake is associated with higher circulating 25-hydroxyvitamin D, apparently by slowing its catabolic clearance rather than by adding vitamin D. This is an association, not a demonstrated cause.

Fat-soluble vitamins share micellar solubilisation and the same intestinal transport proteins, so a large tocopherol dose in the same capsule can modestly lower vitamin D uptake.

The active metabolite upregulates intestinal calcium transport, and citrate-bound calcium dissolves without needing gastric acid, so the two work well in the same dose.

The active metabolite increases intestinal uptake of phosphate as well as calcium, and low serum phosphate stimulates renal conversion of calcifediol to the active form through FGF23 and parathyroid hormone signalling. Phosphorus intake therefore sits inside the same regulatory loop rather than beside it. This is settled endocrine physiology, not a combination trial.

Fat-soluble vitamin absorption depends on micelle formation in the small intestine, which requires dietary fat and bile. Calcifediol is more polar than cholecalciferol and less dependent on that process, but a lipid vehicle is still the conventional carrier. The mechanism is established for the class.

Without bile salts, dietary lipid and the fat-soluble vitamins dissolved in it are not packaged into the mixed micelles that present them to the enterocyte. Anyone with reduced bile output absorbs this class less well. Calcifediol's greater polarity makes it less dependent on this step than cholecalciferol, which is a difference worth stating rather than glossing.

Triglyceride must be hydrolysed before its products can assemble into micelles with bile salts. Fat-soluble vitamin uptake rides on that process. The relevance is to people whose fat digestion is compromised, and it is a mechanistic statement about the class.

Lecithin lowers interfacial tension and helps a lipophilic molecule stay dispersed rather than separating out of a formulation. It is a formulation choice rather than a nutrient interaction. Whether it changes absorption in practice depends on the specific preparation.

Strontium is absorbed by the same transport routes as calcium and deposits into bone mineral in its place, so the two compete when taken together. A vitamin D metabolite that increases calcium absorption will also increase strontium absorption through the same route. Separating strontium from calcium and vitamin D dosing is the usual practice for this reason.

Vitamin D metabolites increase transcription of osteocalcin and matrix Gla protein, both of which need vitamin K-dependent gamma-carboxylation of glutamate residues before they can bind calcium. Making more of a protein that cannot be carboxylated leaves it uncarboxylated. K1 is the plant form of the vitamin and shares that cofactor role with the menaquinones.

Calcifediol increases the fraction of dietary calcium absorbed, so the same calcium supplement delivers more when it is present. That is the intended combination in most bone formulas, and it is also why total intake and serum calcium are the numbers to watch. The additive effect is on absorbed calcium, a measured quantity, not on any outcome.

Ergocalciferol is hydroxylated in the liver to 25-hydroxyvitamin D2, while calcifediol is already at the 25-hydroxy stage. Taking both raises total 25-hydroxyvitamin D through one metabolite pool. Total vitamin D activity from all sources is the figure to count, not each label in isolation.

Both the 25-hydroxylation and the 1-alpha-hydroxylation steps require magnesium, as does the vitamin D binding protein interaction. Calcifediol arrives already 25-hydroxylated, so it bypasses the first of those steps but still needs the renal one for activation. The cofactor requirement is established biochemistry.

Carotenoids occupy space in the same mixed micelles that carry fat-soluble vitamins, and competition among lipophilic compounds for that capacity is documented within the carotenoid class. Whether a supplemental carotenoid dose meaningfully affects calcifediol uptake is not established. Read the row as a shared-route note.